IVVD Novinky na Forexe
Invivyd Announces Positive 180-day Clinical Efficacy Data From CANOPY Phase 3 Trial Of Pemivibart
Biopharmaceutical company Invivyd, Inc. (IVVD) announced Tuesday positive 180-day clinical efficacy data from the company's ongoing CANOPY Phase 3 clinical trial of pemivibart, a half-life extended investigational monoclonal antibody (mAb), for the pre-exposure prophylaxis (PrEP) of COVID-19.
RTTNews
|
Pred 133 dňami
Invivyd Appoints William Duke As New CFO
Biopharmaceutical company Invivyd, Inc. (IVVD) announced Tuesday the appointment of William Duke as Chief Financial Officer. Duke will lead Invivyd's financial strategy to support the company's continued growth.
RTTNews
|
Pred 490 dňami
